Skip to main navigation
Skip to search
Skip to main content
Sort by
Medicine and Dentistry
Prostate Cancer
100%
Partial Nephrectomy
57%
Neoplasm
53%
Bladder Cancer
45%
Transurethral Resection
41%
Recurrent Disease
40%
Chemotherapy
37%
Prostate Specific Antigen
35%
Transitional Cell Carcinoma
35%
Alanine Aminotransferase
34%
Tumor
32%
Bladder
32%
Mycobacterium Bovis BCG
30%
Bladder Tumor
26%
Radiation Therapy
26%
Sarcopenia
26%
Biochemical Recurrence
25%
Frailty
25%
Invasive Bladder Cancer
22%
Hypofractionated Radiotherapy
22%
Nephron Sparing Surgery
22%
Fibronectin
22%
Urinary System
22%
Hematuria
22%
Cystectomy
21%
Overall Survival
20%
Renal Artery
19%
Cystoscopy
19%
Urine Cytology
19%
Treatment Outcome
19%
Muscle Invasive Bladder Cancer
19%
Clinical Trial
18%
Pseudoaneurysm
17%
Radical Nephrectomy
17%
Median Follow Up
16%
Kidney Tumour
15%
Diseases
15%
Effective Treatment
15%
Tumor Recurrence
15%
Surgical Margin
14%
Lymphocyte
14%
Biopsy Technique
13%
Disease Exacerbation
13%
Bleeding
13%
Kidney Function
13%
Seminal Vesicle
12%
Prostatectomy
12%
Cohort Analysis
12%
Embolization
11%
Cancer Cell
11%
Keyphrases
Prostate Cancer
46%
Prostate-specific Antigen
41%
Laparoscopic Partial Nephrectomy
34%
Non-muscle Invasive Bladder Cancer (NMIBC)
25%
Prostate Cancer Patients
23%
Alanine Aminotransferase
22%
Nephron-sparing Surgery
22%
Human Prostate
22%
Docetaxel
22%
Estramustine Phosphate
22%
Invasive Bladder Cancer
22%
Gemcitabine
22%
Transurethral Resection of Bladder Tumor (TURBT)
17%
Sarcopenia
17%
Overall Survival
17%
Tumor
16%
Bladder Transitional Cell Carcinoma
16%
Upper Tract Urothelial Carcinoma
16%
Prostate-specific Antigen Level
15%
Frailty
15%
Renal Artery Pseudoaneurysm
15%
Prostate Carcinoma
15%
Chemotherapy
15%
Computed Tomography
14%
Partial Nephrectomy
13%
Transurethral Resection
13%
Dose-limiting Toxicity
13%
Radical Cystectomy
13%
Phase II Trial
13%
Metastatic Prostate Cancer
13%
Retrospective Review
13%
Bladder Cancer Patients
13%
Clinical Outcomes
12%
Bacillus Calmette
12%
Short-term Survival
12%
Postoperative Outcomes
12%
Radical Prostatectomy
12%
Total Prostate-specific Antigen
12%
Cancer Patients
12%
Retrospective Analysis
12%
Hematuria
11%
Fibronectin
11%
Superficial Transitional Cell Carcinoma
11%
Hypofractionated Radiation Therapy
11%
Cancer Survivors
11%
Bicalutamide
11%
Lymphocyte Activation
11%
Intravesical Gemcitabine
11%
Perioperative Complications
11%
Primary Care Physicians
11%
Pharmacology, Toxicology and Pharmaceutical Science
Prostate Cancer
71%
Prostate Specific Antigen
38%
Androgen
28%
Gemcitabine
22%
Prostate Tumor
22%
Docetaxel
22%
Estramustine Phosphate
22%
Pharmacokinetics
17%
Transitional Cell Carcinoma
14%
Neoplasm
14%
Bladder Cancer
14%
Disease Exacerbation
14%
Chemotherapy Regimens
13%
Fibronectin
11%
Mycobacterium Bovis BCG
11%
Bicalutamide
11%
Prostate Hypertrophy
11%
Hyperthermia
11%
Bisphosphonic Acid Derivative
11%
Non Muscle Invasive Bladder Cancer
11%
Tamsulosin
11%
Castration Resistant Prostate Cancer
11%
Mitomycin
11%
Alpha Adrenergic Receptor Blocking Agent
11%
Marimastat
11%
Melatonin Receptor
11%
Lanoteplase
11%
Izonsteride
11%
Alfuzosin
11%
Melatonin
11%
Prostate Carcinoma
11%
Clinical Pharmacology
11%
Diethylstilbestrol
11%
Steroid 5alpha Reductase Inhibitor
11%
Erectile Dysfunction
11%
Anticarcinogen
11%
DNA Topoisomerase
11%
Schizophrenia
11%
Scleroderma
11%
Systemic Sclerosis
11%
Recurrent Disease
8%
Antiandrogen
8%
Osteopenia
7%
Diseases
6%
Enzyme-Linked Immunosorbent Assay
6%
Side Effect
6%
Thromboembolism
5%
Diarrhea
5%
Neutropenia
5%
Testosterone
5%
